NCT06807190 is a clinical trial of Insulin Icodec in Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT06807190?

NCT06807190 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT06807190?

Interventions in NCT06807190: Insulin Icodec.

What condition does NCT06807190 study?

NCT06807190 studies Diabetes Mellitus, Type 1.

Is NCT06807190 still recruiting?

NCT06807190 is currently recruiting now. Last updated 9 April 2026.

Last reviewed 2026-04-09 · How we verify

NCT06807190

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus

Recruiting now Last updated 9 April 2026

What this trial tests

trial testing Insulin Icodec in Diabetes Mellitus, Type 1 in 630 participants. Currently enrolling.

Timeline

30 May 2025

Primary endpoint
31 July 2027

31 January 2028

Quick facts

Lead sponsor	Novo Nordisk A/S
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	630
Start date	30 May 2025
Primary completion	31 July 2027
Estimated completion	31 January 2028
Sites	80 locations across Japan

Drugs / interventions tested

Insulin Icodec — full drug profile →

Conditions studied

Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Eligibility, any sex, with Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to investigate the safety and effectiveness of Awiqli in participants with diabetes mellitus under real world clinical practice in Japan. Participants will get Awiqli as prescribed by the study doctor. The study will last for about 1 year.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy and safety of once-weekly basal insulin therapy in people with type 1 diabetes: A systematic review and meta-analysis.
Di Gioia L, Di Molfetta S, Caruso I, Caporusso M, et al · · 2026 · cited 1× · PMID 41048193 · DOI 10.1111/dom.70176
Emerging perspectives on once-weekly insulins in type 1 and type 2 diabetes: a mini-review.
Denimal D. · · 2025 · cited 1× · PMID 40937414 · DOI 10.3389/fendo.2025.1656884

Verify or expand the search:

Other trials of Insulin Icodec

Trials testing the same drug.

NCT05813912 — A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the · Phase 3 · completed
NCT05823948 — A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes W · Phase 3 · completed
NCT04770532 — A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, I · Phase 3 · completed
NCT04582435 — A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Insulin Icodec in Subjects With Type 2 Diabe · Phase 1 · completed

Other recruiting trials for Diabetes Mellitus, Type 1

Currently open trials in the same condition.

NCT07325461 — Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes · NA · recruiting
NCT07305805 — A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes · Phase 1 · recruiting
NCT06282055 — Trajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes · recruiting
NCT06325202 — Closed Loop and Education for Hypoglycemia Awareness Restoration · NA · recruiting
NCT07160816 — A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06807190 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 9 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06807190.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing